This roll-over protocol allows patients who are still receiving clinical benefit to continue
to be treated from multiple protocols in one program spanning multiple indications during the
completion of the parent study/(ies). The population for the roll-over study should be
consistent with the population defined in the program parent study/(ies). The primary
eligibility criteria for a patient to enter the roll-over protocol is the participation and
completion of a Novartis GDD&GMA/Incyte study with ruxolitinib monotherapy or combination of
ruxolitinib and panobinostat. Efficacy parameters would not be measured; however safety data
and an evaluation of clinical benefit will be collected.
Patients who have completed a prior study with ruxolitinib monotherapy or combination of
ruxolitinib and panobinostat and who are assessed by the Investigator to continue to benefit
from ongoing treatment will be eligible.